Earlier, we studied the role of GRIN2A and GRIN2B variants in antipsychotic-induced tardive dyskinesia in schizophrenia in terms of genetically determined increase in vulnerability to NMDA-induced excitotoxicity [17,18,19]. The gene discussed is GRIN2B; the disease is schizophrenia.